Indications
Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.
Composition
- Active substance
- raltegravir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Isentress
- Active substance
- raltegravir
- ATC code
- J05AJ01
- Therapeutic area
- HIV Infections
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- EU authorisation
- 19 Dec 2007